Head & neck · 2026
Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Tatsuya, Omura Go, Fushimi Chihiro, Sakai Toshihiko, Sakai Azusa, Eguchi Kohtaro, Hayashi Takaaki, Watanabe Takane, Tanaka Akihisa, Katoh Mitsuhiko, Imazeki Hiroshi, Yamamoto Shun, Honma Yoshitaka, Takahashi Hideaki, Kato Ken, Yoshimoto Seiichi
Аннотация
BACKGROUND: To evaluate the therapeutic effect of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (NeoDCF), the standard treatment for stage IB-III esophageal squamous cell carcinoma (ESCC), against synchronous superficial pharyngeal squamous cell carcinoma (PSCC).
METHODS: We retrospectively reviewed ESCC patients with synchronous early-stage PSCC who received NeoDCF. The primary endpoint was disease-specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.
RESULTS: Among 786 patients with ESCC, 58 (7.4%) had synchronous early-stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3-year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups (p = 0.67).
CONCLUSIONS: NeoDCF demonstrated excellent efficacy against early-stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.
METHODS: We retrospectively reviewed ESCC patients with synchronous early-stage PSCC who received NeoDCF. The primary endpoint was disease-specific survival (DSS) for PSCC. Secondary endpoints included overall survival (OS), local tumor response, and time to progression (TTP) of PSCC.
RESULTS: Among 786 patients with ESCC, 58 (7.4%) had synchronous early-stage PSCC. Local tumor response was complete disappearance in 33 (57%) patients, partial reduction in 24 (41%), and no change in 1 (2%). The 3-year DSS, OS, and TTP were 100%, 61%, and 78%, respectively. No significant difference was found between the Tis and T1/T2 groups (p = 0.67).
CONCLUSIONS: NeoDCF demonstrated excellent efficacy against early-stage PSCC, supporting prioritization of ESCC treatment with timely local intervention for recurrent PSCC.
Предметные рубрики MeSH
HumansFluorouracilCisplatinDocetaxelEsophageal NeoplasmsRetrospective StudiesNeoadjuvant TherapyFemaleMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellTaxoidsNeoplasm StagingAgedHypopharyngeal NeoplasmsOropharyngeal NeoplasmsNeoplasms, Multiple PrimaryTreatment OutcomeAdult